Clinical trial
Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are…
NCT00002441 · VaxGen, Industry · Completed
Key facts
| NCT number | NCT00002441 |
|---|---|
| Title | Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection |
| Official title | A Phase III Trial to Determine the Efficacy of Bivalent AIDSVAX B/B Vaccine in Adults at Risk of Sexually Transmitted HIV-1 Infection in North America |
| Lead sponsor | VaxGen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, HIV Seronegativity |
| Intervention type | Biological |
| Interventions | MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 |
| Enrollment | 5,000 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | Canada, Netherlands, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: